Nuvalent, Inc. (NUVL)
NASDAQ: NUVL · Real-Time Price · USD
108.01
+0.88 (0.82%)
At close: Nov 20, 2025, 4:00 PM EST
105.93
-2.08 (-1.93%)
After-hours: Nov 20, 2025, 6:22 PM EST
Nuvalent Employees
Nuvalent had 142 employees as of December 31, 2024. The number of employees increased by 50 or 54.35% compared to the previous year.
Employees
142
Change (1Y)
50
Growth (1Y)
54.35%
Revenue / Employee
n/a
Profits / Employee
-$2,686,162
Market Cap
7.85B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 142 | 50 | 54.35% |
| Dec 31, 2023 | 92 | 30 | 48.39% |
| Dec 31, 2022 | 62 | 22 | 55.00% |
| Dec 31, 2021 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NUVL News
- 1 day ago - Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC - PRNewsWire
- 2 days ago - Nuvalent Announces Pricing of Public Offering of Common Stock - PRNewsWire
- 3 days ago - Nuvalent Announces Public Offering of Common Stock - PRNewsWire
- 3 days ago - Nuvalent, Inc. (NUVL) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer Transcript - Seeking Alpha
- 3 days ago - Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer - Benzinga
- 3 days ago - Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC - PRNewsWire
- 6 days ago - Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib - PRNewsWire
- 16 days ago - Nuvalent: Interesting Product, But Aggressive Valuation - Seeking Alpha